R ecommended as first line agents in most hypertension guidelines, 1,2 thiazide-related diuretics are particularly useful in resistant and salt-sensitive forms of hypertension, the latter group accounting for half of all hypertension, including black, elderly, obese, and diabetic patients. 3,4 However, not all thiazide-related medications have the same properties, and many studies have contrasted the most widely used thiazide diuretic, hydrochlorothiazide (HCTZ), and the thiazide-like diuretic, chlorthalidone (CTDN), with respect to duration of action, antihypertensive potency, nonblood pressure-related pleiotropic features, reduction of left ventricular hypertrophy, and reduction of cardiovascular events. 5 These studies have been accompanied by many helpful commentaries contrasting the 2 medications. However, relatively little is known as to how HCTZ compares with another thiazide-like medication, indapamide (INDAP), even though both INDAP and CTDN have been recommended in place of HCTZ.
R ecommended as first line agents in most hypertension guidelines, 1,2 thiazide-related diuretics are particularly useful in resistant and salt-sensitive forms of hypertension, the latter group accounting for half of all hypertension, including black, elderly, obese, and diabetic patients. 3, 4 However, not all thiazide-related medications have the same properties, and many studies have contrasted the most widely used thiazide diuretic, hydrochlorothiazide (HCTZ), and the thiazide-like diuretic, chlorthalidone (CTDN), with respect to duration of action, antihypertensive potency, nonblood pressure-related pleiotropic features, reduction of left ventricular hypertrophy, and reduction of cardiovascular events. 5 These studies have been accompanied by many helpful commentaries contrasting the 2 medications. However, relatively little is known as to how HCTZ compares with another thiazide-like medication, indapamide (INDAP), even though both INDAP and CTDN have been recommended in place of HCTZ. 6 Therefore,
we conducted a systematic review and meta-analysis of headto-head randomized controlled trials to address this question. In addition, head-to-head trials contrasting HCTZ with CTDN were analyzed to further quantify the relative potency of those 2 drugs and to place the HCTZ-INDAP comparisons in context.
to standing BP only, drug dose titrated to effect on the outcome; follow-up <2 weeks; and follow-up >6 months (because such trials are likely to be focused on other outcomes and therefore might measure blood pressure less rigorously). Sitting BP was chosen over supine BP where both were given. Trials were limited to diuretics at commonly prescribed doses (online-only Data Supplement).
To make fair comparisons between drugs, the diuretic dose in milligrams in each arm was classified according to 3 dose levels (or steps) using 10 different sources (Section 1 and Table S1 
Results
The search yielded 9765 references ( Figure S1 ) of which were 14 eligible trials: 10 with HCTZ-INDAP comparisons of SBP, 3 with HCTZ-CTDN comparisons of SBP, and 9 with HCTZ-INDAP comparisons of metabolic parameters (Table 1) . [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] No trials compared CTDN with INDAP, and all trials lacked cardiovascular events as outcomes. Contrasting CTDN with HCTZ on metabolic effects was lacking. Table 1 Relative to HCTZ, INDAP produced a greater reduction in SBP: −5.1 mm Hg (95% CI, −8.7 to −1.6), P=0.004 (Figure 1 ). There was minimal heterogeneity across the 10 trials. Because of substantial differences in dose levels for the 2 drugs, the result was biased in favor of HCTZ having a greater potency than INDAP (description in Figure 1 and Table S3 ). INDAP and HCTZ were not detectably different in their effects on serum potassium (Figure 2 ). Relative differences in other metabolic effects are shown in Table 2 . As with potassium, there were no detectable differences between HCTZ and INDAP for these metabolic effects.
Results for sensitivity analyses are as follows: (1) (Figure 1 ).
11 (6) The 3 largest trials showed a mean SBP reduction of −6.4 (−11.1 to −1.7).
11,17,18
Contrasting HCTZ with CTDN also showed a greater reduction in SBP from CTDN compared with HCTZ: −3.6 (95% CI, −7.3 to 0.0), P=0.052 (Figure 3 ). The trial with the narrowest SE (and also the largest number) showed a difference of −2.5 (−6.9 to 1.89). The trial with the highest quality had the greatest reduction in SBP by CTDN relative to HCTZ: −6.3 (−16.3 to 3.7). There was again no evidence for publication bias for this comparison ( Figure S3b ).
Discussion
These head-to-head comparisons demonstrate that, at commonly used doses, INDAP lowers SBP more than HCTZ without evidence for greater adverse effects. There was also evidence (although limited to fewer patients) that CTDN was more potent than HCTZ. Compared with an estimated 9.5-mm Hg reduction in SBP from HCTZ relative to placebo from Peterzan et al, 24 INDAP and CTDN lowered SBP by 54% and 38% more than HCTZ, respectively. The advantage in antihypertensive potency of INDAP compared with HCTZ was probably underestimated because of the much greater weight on the overall effect from trials in which HCTZ was given at a higher dose level than INDAP. This HCTZ-CTDN headto-head synthesis is consistent with the masterful but indirect comparisons of previous meta-analyses. 24, 25 The present HCTZ-INDAP head-to-head findings have apparently not been reported previously. Although these studies lacked cardiovascular events as outcomes, there are other relevant data. INDAP has reduced left ventricular mass index by 17% (P<0.001), whereas HCTZ had no significant effect on this end-organ process. 26 INDAP's reduction of left ventricular hypertrophy has been repeatedly demonstrated and is more pronounced than that of enalapril. 27 Furthermore, INDAP was found to be comparable with captopril and enalapril in reducing albuminuria in diabetes mellitus, 28 whereas in another study, HCTZ had no effect on this pathology. 29 Compared with HCTZ, INDAP is more effective in scavenging oxygen radicals and in inhibiting platelet aggregation. 30, 31 For reducing cardiovascular events, in the PATS (Post Stroke Antihypertensive Treatment Study) trial, 2.5 mg of INDAP reduced stroke by 29% and all cardiovascular events by 23% versus placebo. 32 In the PROGRESS (Preventing Strokes by Lowering Blood Pressure in Patients With Cerebral Ischemia) trial, only when INDAP was added to perindopril was there a reduction in risk of stroke. 33 The perindopril-INDAP combination also reduced cardiovascular events in 2 other placebocontrolled trials. 34, 35 In contrast, in the Oslo study, compared with an untreated control group, the HCTZ arm (65% of whose patients were on one or more additional antihypertensives) significantly reduced the risk of stroke but not coronary artery disease or all cardiovascular events combined. 36 HCTZ was inferior to enalapril and amlodipine in head-to-head trials and inferior to CTDN in network analysis. 5 Although HCTZ has less than a 24-hour duration of diuretic and antihypertensive action, 5,20 the duration of antihypertensive action for INDAP immediate-release and INDAP sustained release is estimated as 24+ hours and 32+ hours, respectively. 37 This is important because targeting night-time BP may reduce cardiovascular events more than targeting daytime BP. [38] [39] [40] In spite of greater antihypertensive potency, INDAP did not have a detectably greater effect than HCTZ on metabolic adverse effects. Findings regarding serum potassium are consistent with previous studies showing declines in serum potassium from INDAP immediate-release 2.5 mg of −0.30 to −0.42 mEq/L, 41, 42 similar to the decline found with HCTZ 25 mg. 24, 25 Unlike HCTZ, INDAP has no effect on serum lipids. 43 Initially, thiazide-related diuretics lower BP via diuretic effects, but ultimately, their antihypertensive effects stem from decreased peripheral arterial resistance through unknown mechanisms. 3 In contrast, INDAP is known to also operate via a direct vasodilator effect from inhibitory activity against vasopressors and decreased inward flow of calcium ions in vascular smooth muscle. 44 Consistent with this mechanism, INDAP reduces BP in end-stage renal disease, unlike HCTZ. 45 At 2.5 mg per day, INDAP has been described as a weak diuretic. However, its natriuretic and aquaretic effects are dose related. Doubling the dose to 5 milligrams daily promotes volume loss, similar to the effect of 40 mg of furosemide. 46 Thus, at the 5-mg dose, INDAP would address the salt and volume excess of resistant hypertension (as well as provide optimal antihypertensive potency) and would also be a useful diuretic for salt-sensitive hypertension.
Limitations of this study include the wide CIs reflecting some limitations in statistical power, the absence of 24-hour blood pressure measurements (which are better predictors of cardiovascular events), and the absence of cardiovascular events as outcomes. Also, half of the weight for the HCTZ-INDAP comparison came from 1 trial. 11 In addition, these results must be properly interpreted: this analysis does not demonstrate that INDAP is more efficacious than HCTZ for reducing SBP (ie, that INDAP's superiority is maintained when the 2 drugs are given at high doses). Strengths of this study are the head-to-head rather than indirect comparisons, the consistency of effects (ie, the relatively small values for τ and I 2 in Figure 1 ), the verification of the results by the several sensitivity analyses, and the lack of evidence for publication bias. Removing the trial contributing half of the weight to the HCTZ-INDAP comparison leads to a result even more in favor of INDAP: SBP reduction of −6.1 (95% CI, −10.1 to −2.1). Although this analysis does not show that CTDN is more efficacious than HCTZ, this synthesis does show that INDAP is more potent than HCTZ at commonly prescribed dose levels. 
Perspectives
In 2013 in the United States, there were 50 million prescriptions for HCTZ making this the 12th most commonly prescribed drug. 47 However, HCTZ has lesser antihypertensive potency as shown here and has several other types of deficiencies. 5 CTDN is generally offered as the alternative, and the present results, based on head-to-head trials, confirm CTDN's superiority reported from indirect HCTZ-CTDN comparisons. However, in countries such as the United States, clinicians may avoid CTDN because it has only 1 unscored dose preparation, which is at the maximum recommended dose, making it an impractical choice for many patients. In contrast, INDAP has low and intermediate dose formulations and, in Europe, is also available in slow release, thus giving it much greater flexibility than CTDN. Like CTDN ($19 per month), INDAP immediate-release is relatively inexpensive at $4 per month. Although US guidelines for the management of resistant hypertension advocate CTDN, 3 this analysis implies that INDAP should also be preferred compared with HCTZ for this condition. In addition, these results support the view that CTDN and INDAP are preferable to HCTZ for managing hypertension in general.
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What Is New?
This study synthesizes trials on the relative potency of hydrochlorothiazide (HCTZ) and indapamide for the first time. Although indirect comparisons have compared HCTZ and chlorthalidone with respect to antihypertensive potency, this synthesis is the first to compare head-to-head randomized trials.
What Is Relevant?
HCTZ is the 12th most commonly prescribed drug in the United States, with 50 million prescriptions annually for monotherapy alone. Chlorthalidone is commonly cited as the alternative to HCTZ; this analysis confirms chlorthalidone's superior antihypertensive potency. This study demonstrates for the first time that indapamide is ≈50% more potent than HCTZ.
In countries such as the United States, chlorthalidone has only 1 dosage form, an unscored, maximum dose tablet. Because indapamide has ≥2 dosage forms in the low-to-intermediate dose range, it is a more appropriate alternative to HCTZ in many instances. These features apply to resistant hypertension and to the treatment of hypertension in general.
Summary
Based on an analysis of head-to-head trials, indapamide and chlorthalidone are more potent than HCTZ in lowering systolic blood pressure.
